Executive at Cue Biopharma (CUE) granted 100K stock options

Rhea-AI Filing Summary

Cue Biopharma, Inc. reported that Chief Development Officer Daniel G. Baker received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.

The award vests over four years, with 25% of the options vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Baker holds 100,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Baker Daniel G.

Role CHIEF DEVELOPMENT OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	100,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 100,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 100,000 options Exercise price: $0.29 per share Expiration date: April 8, 2036 +3 more

6 metrics

Option grant size 100,000 options Stock Option (right to buy) awarded to CDO Daniel G. Baker

Exercise price $0.29 per share Conversion or exercise price of granted stock options

Expiration date April 8, 2036 Option term end date for this grant

Underlying shares 100,000 shares Common Stock underlying the stock option grant

Post-grant derivative holdings 100,000 options Total derivative securities held after transaction

Initial vesting 25% after 1 year Portion of options vesting on first anniversary of grant date

Key Terms

Stock Option (right to buy), exercise price, vesting, Common Stock, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 0.2900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

expiration date financial

"expiration_date: 2036-04-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baker Daniel G.

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF DEVELOPMENT OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.29	04/09/2026		A		100,000		(1)	04/08/2036	Common Stock	100,000	$0.0	100,000	D

Explanation of Responses:

1. This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.

	/s/ Daniel G. Baker by Colin Sandercock, attorney-in-fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cue Biopharma (CUE) report for Daniel G. Baker?

Cue Biopharma reported that Chief Development Officer Daniel G. Baker received a grant of stock options for 100,000 shares of Common Stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What is the exercise price of Daniel G. Baker’s new Cue Biopharma stock options?

The granted stock options have an exercise price of $0.29 per share. This means Baker can, once vested and until expiration, purchase Cue Biopharma Common Stock at $0.29 per share regardless of the market price at that time.

How do Daniel G. Baker’s Cue Biopharma options vest over time?

The options vest over four years. 25% of the award vests on the first anniversary of the grant date, and the remaining 75% vests in equal semi-annual installments thereafter, aligning the award with multi-year service at the company.

When do Daniel G. Baker’s Cue Biopharma stock options expire?

The stock options expire on April 8, 2036. After that expiration date, any unexercised portion of the 100,000-share option grant will lapse, and Baker will no longer be able to purchase shares under this specific option award.

How many Cue Biopharma derivative securities does Daniel G. Baker hold after this Form 4?

Following this grant, Daniel G. Baker holds 100,000 stock options directly, each tied to one share of Cue Biopharma Common Stock. The filing does not list additional derivative positions in the derivative holdings summary for this reporting person.